Ambalal Sarabhai Enterprises is a holding company that doesn’t make anything itself - it builds focused subsidiary businesses, each with its own factory and market, and then steps back. It began as a single Indian pharmaceutical house and has since spun out a web of eight subsidiaries and two joint ventures, all following the same playbook: isolate a niche, give it dedicated manufacturing, and push for regulated export markets. That recurring approach - demerge, focus, and chase global regulatory approvals - explains everything from its fermentation-based antifungal plant to its newest molecular diagnostics factory.
Business segments
Three engines at different stages - a pharmaceuticals platform built on fermentation and oncology APIs, a diagnostics joint venture scaling from PCR kits to rapid cards, and an electronics subsidiary that makes lab instruments and distributes broadcast gear - each housed in its own dedicated entity.
1. Pharmaceuticals: where the group’s manufacturing depth and export licences live
A cluster of five subsidiary factories makes everything from fermentation-based antifungals to oncology APIs and effervescent tablets, with the most valuable products sold into regulated US and European markets.
- The only Indian maker of a critical antifungal - Synbiotics Limited operates a USFDA-inspected fermentation plant that manufactures Amphotericin B API, and it is the sole producer of this drug in India; during the post-Covid mucormycosis crisis it ramped up capacity to meet national demand.
- Oncology APIs from a freshly demerged plant - Asence Pharma Private Limited, a subsidiary of the Company, commenced its new oncology and synthetic API plant at Ranoli, Vadodara, on June 8, 2023, which is set up to meet domestic and international regulatory standards.
- An international front-end with over 100 registrations - Asence Inc., the group’s US subsidiary, markets finished dosage forms and APIs worldwide and is developing novel products for Europe and the US using the group’s Indian factories, giving the manufacturing subsidiaries a direct pipeline to regulated markets.
- Effervescent tablets from a USFDA-approved joint venture - Vovantis Laboratories runs a recently built, USFDA-approved facility at Ranoli that makes effervescent dosage forms for global sale, with the USA as its priority market.
- Domestic generics, veterinary products, and Vitamin C - three smaller subsidiaries fill out the portfolio: Suvik Hitek manufactures generics and veterinary formulations for India, Sarabhai M Chemicals makes Vitamin C coated products at Ranoli, and Sarabhai Chemicals markets specialty oncology and women’s healthcare brands across India while pivoting toward online OTC retailing after the demerger.
2. Diagnostics: a joint venture that prints money from PCR and rapid tests
CoSara Diagnostics holds exclusive Indian manufacturing rights to its US partner’s entire molecular test menu, and it is now building its own raw-material supply to escape dependence on imported primers.
- Exclusive licence from a US biotech - the joint venture with Co-Diagnostics Inc. gives CoSara the sole right to manufacture and sell the American partner’s full infectious-disease PCR kit range in India, effectively a protected franchise.
- More than fifteen molecular tests already on the market - its joint venture CoSara Diagnostics Pvt. Ltd. produces PCR kits at its plant in Ranoli, Gujarat, sold across India under the SARAQ™ brand, covering COVID-19, Chikungunya, Dengue (all four serotypes), and Hepatitis C viral load, with the HCV kit being its 14th CDSCO-approved product.
- A rapid-test card range added in 2023 - under the Saragene™ and Saraplex™ brands, CoSara now sells lateral-flow card tests for HIV (with differential detection of types 1 and 2), Hepatitis B and C, Syphilis, Malaria, Dengue, and Typhoid, giving it a presence in the faster, lower-cost segment.
- Backward integration into primers - in December 2024 it opened an OligoNucleotides synthesis facility at Ranoli to manufacture its patented CoPrimer chemistry in-house, reducing reliance on expensive imported primers and probes and paving the way to build a portable PCR point-of-care device for TB and HPV screening.
- Gates Foundation-funded pipeline - Co-Diagnostics Inc. has received grants from the Bill & Melinda Gates Foundation for TB and HPV tests on a portable PCR platform, and CoSara expects to extend its partnership to cover R&D and future manufacturing of those products at its Indian plant.
3. Electronics: lab instruments and broadcast distribution under one roof
Systronics India makes analytical instruments for Indian labs and classrooms, while its Telerad division acts as a legacy distributor of Sony and other professional broadcast brands - two steady, domestically focused cash streams.
- A domestic manufacturer of lab instruments - the Systronics division produces analytical and test-and-measurement instruments at its Naroda, Ahmedabad plant, selling to educational institutions, industrial labs, and research centres across India, with new products launched regularly.
- Sony’s oldest Indian representative - the Telerad division distributes professional broadcast, video, and audio equipment from Sony and other international brands such as Roland, Sennheiser, and Haivision to India’s media and broadcasting sector, a relationship built over decades.
Group structure and partners
Every operating business sits in its own subsidiary or joint venture, and the group has repeatedly used demergers to isolate high-potential divisions - the parent company itself carries out no production.
- Eight subsidiaries, two joint ventures, one associate - the operating entities span pharmaceuticals, diagnostics, electronics, and a container associate, with the parent ASE functioning purely as a listed holding company.
- The oncology demerger created a pure-play API company - in October 2024 the NCLT sanctioned the split of Sarabhai Chemicals’ oncology and pro-fertility division into Asence Pharma, leaving the former to focus on domestic OTC retailing while Asence Pharma pursues regulated export markets from its dedicated Ranoli plant.
- Synbiotics was pushed down into a step-down subsidiary - in 2021 ASE transferred its 99.99% stake in Synbiotics to Asence Pharma, paid for partly with preference shares and partly with a long-dated payable, so that the fermentation business now sits deeper in the group structure under the international pharma arm.
- CoSara’s US partner is exploring a SPAC - Co-Diagnostics Inc. engaged Maxim Group in late 2025 to pursue a SPAC transaction or similar strategic alternative for CoSara, signalling a potential liquidity event for the diagnostics joint venture.